Molecular vulnerabilities and therapeutic resistance in hormone receptor positive and HER2 dependent breast cancer tumours

Over the past two decades, high sensitivity to HER2-amplified primary breast cancers has been achieved with HER2-targeted therapies. CDK4/6 inhibitors have long been identified as a potential treatment option for advanced breast cancer patients. However, acquired HER2 heterogeneity leading to resist...

Descripción completa

Detalles Bibliográficos
Autores principales: Velaga, Ravi, Tanaka, Sunao, Toi, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255254/
https://www.ncbi.nlm.nih.gov/pubmed/35800379
http://dx.doi.org/10.20517/cdr.2022.10

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255254/
https://www.ncbi.nlm.nih.gov/pubmed/35800379
http://dx.doi.org/10.20517/cdr.2022.10

Ejemplares similares